US › Healthcare

Lisata Therapeutics Inc. (LSTA)

US · Healthcare · Biotechnology

$1.14+9.62%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-4.5M
Profit YoY
+5.0%
EPS
$-0.33
EPS estimate
$0.00

Key statistics

Market cap
$9.0M
Forward P/E
2.7
P/B
0.83
Book value
$1.20
EPS (TTM)
$-1.86
52-week high
$5.07
52-week low
$0.99
50-day MA
$3.08
200-day MA
$3.26
Beta
0.80

Analyst view

Analysts rate Lisata Therapeutics Inc. a buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $4.00.

Shareholding

Insiders
20.89%
Institutions
11.35%

Largest institutional holders

FundStake
Vanguard Capital Management, LLC2.98%
Renaissance Technologies Corp1.45%
Deltec Asset Management LLC0.91%
Geode Capital Management, LLC0.78%
Css LLC0.68%
BlackRock Inc0.60%
Penderfund Capital Management Ltd0.52%
Virtu Financial LLC0.46%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Lisata Therapeutics Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.